From Junior Mints to robotics, the state already produces more than you think - but the next economic development chief needs ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

How TIME and Statista Determined the World's Most Sustainable Companies of 2025 In the fight against climate change, ...

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

DREAMS-2: A Phase 3 study comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on ...

Sridhar Babu highlighted that the project was aligned with the vision of Chief Minister A Revanth Reddy to position Telangana ...

Discover what makes Paris's biotech ecosystem so successful, as it just so happens to be one of the largest biotech clusters ...